Dr. Alexander Brown, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Uniformed Services Uhs Fe Hebert School of Med (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 624
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Uniformed Services Uhs Fe Hebert School of Med
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME131710
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sacred Heart Hospital Pensacola, FL
- Baptist Hospital Pensacola, FL
- Gulf Breeze Hospital Gulf Breeze, FL
- Santa Rosa Medical Center Milton, FL
- D W Mcmillan Memorial Hospital Brewton, AL
Medical groups
- Sacred Heart Health System Inc (389 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 624
- Services billed
- 1,670
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 823 | 334 |
| Established patient office or other outpatient visit, 20-29 minutes | 314 | 252 |
| Established patient office or other outpatient visit, 40-54 minutes | 116 | 71 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 79 | 36 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 58 | 29 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 41 | 40 |
| New patient office or other outpatient visit, 45-59 minutes | 36 | 36 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | 19 |
| Hospital discharge day management, more than 30 minutes | 18 | 15 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Pensacola, FL | 132 |
| Anastrozole Other prescribers in Pensacola, FL | 118 |
| Oxycodone Hcl Other prescribers in Pensacola, FL | 111 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Pensacola, FL | 110 |
| Ondansetron Hcl Other prescribers in Pensacola, FL | 100 |
| Letrozole Other prescribers in Pensacola, FL | 90 |
| Revlimid (lenalidomide) | 87 |
| Prochlorperazine Maleate Other prescribers in Pensacola, FL | 68 |
| Prednisone Other prescribers in Pensacola, FL | 67 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Pensacola, FL | 65 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 21 payments worth $379 in total to this clinician.
| Celgene Corporation | $51.71 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $42.02 |
| AbbVie Inc. | $36.29 |
| Novartis Pharmaceuticals Corporation | $34.28 |
| Beone Medicines USA, Inc. | $31.85 |
| Janssen Biotech, Inc. | $31.79 |
| Incyte Corporation | $24.07 |
| Jazz Pharmaceuticals Inc. | $20.37 |
| Food and Beverage | $379 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $15,080 in research payments for these studies, mostly to the institutions running them.
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Beigene, Ltd. · Active, not recruiting · NCT05100862 - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously …
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.